UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Introduction UEG Journal and UEG Journal Best Paper Award

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Introduction UEG Journal and UEG Journal Best Paper Award

Joost Drenth 1, Ana Dugic 2, Robert Hüneburg 3

1 Radboudumc University Nijmegen Medical Centre, Nijmegen, Netherlands

2 Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany

3 University Hospital Bonn, Bonn, Germany

Event

UEG Week Copenhagen 2023

Topics

Hepatobiliary

Session

Best of hepatology in UEG Journal

Published

2023
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Management of pregnant women with chronic liver disease: Key points of vigilance

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Management of pregnant women with chronic liver disease: Key points of vigilance

Nathalie Ganne-Carrié 1

1 Hôpital Jean Verdier, APHP et Université Paris 13, Paris, France

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary Paediatrics

Session

Liver and pregnancy: Beware of dangerous liaisons

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Which advanced therapy should you choose in patients with fistulising Crohn's disease?

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Which advanced therapy should you choose in patients with fistulising Crohn's disease?

Krisztina Barbara Gecse 1

1 Amsterdam University Medical Center, Amsterdam, Netherlands

Event

UEG Week Berlin 2025

Topics

IBD Mechanisms & Personalised Medicine Surgery

Session

Focus on fistulising Crohn’s disease 

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Drugs of the future

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Drugs of the future

Severine Vermeire 1

1 University Hospital Leuven, Leuven, Belgium

Event

UEG Week Copenhagen 2023

Topics

Education & Training IBD Small Intestine & Nutrition Surgery

Session

What's new in IBD in 2023?

Published

2023
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
The metabolic nature of inflammatory bowel diseases: From mechanistic insights to precision nutrition

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

The metabolic nature of inflammatory bowel diseases: From mechanistic insights to precision nutrition

Timon Adolph 1

1 Univ.-Klinik für Innere Medizin / Univ.-Klinik für Innere Medizin I, Innsbruck, Austria

Event

UEG Week Copenhagen 2023

Topics

IBD Mechanisms & Personalised Medicine

Session

Prediction of response in IBD

Published

2023
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Re-introducing immune-tolerance to gluten: Does that work for treatment?

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Re-introducing immune-tolerance to gluten: Does that work for treatment?

Knut E.A. Lundin 1

1 Norwegian Coeliac Disease Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway

Event

UEG Week Berlin 2025

Topics

Immunology Nurses Small Intestine & Nutrition

Session

What's new in coeliac disease in 2025?

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025
UEG Presentation
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
APPLICABILITY OF THE INTERNATIONAL BOWEL ULTRASOUND SEGMENTAL ACTIVITY SCORE (IBUS-SAS) TO ULCERATIVE COLITIS: A PROSPECTIVE STUDY

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Introduction

​Intestinal ultrasound (IUS) is gaining increasing acceptance as a reliable tool for tight monitoring of ulcerative colitis (UC). Although several IUS scores have been proposed, none has been formally implemented into official recommendations of international scientific societies.

Aims & Methods

We aimed to compare an IUS score validated for Crohn’s disease (CD), the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS)1, with other IUS scores specifically developed for UC, in terms of correlation with endoscopic activity.
Patients with UC ≥ 18 years old undergoing partial or full colonoscopy between April 2023 and January 2024 were prospectively included. Endoscopic evaluation of at least the sigmoid colon was mandatory for inclusion, and patients with proctitis (Montreal E1) were excluded. Endoscopic activity was scored with both the Mayo Endoscopic Subscore (MES) and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and defined by MES ≥ 1 and UCEIS ≥ 2. Moderate endoscopic activity was determined by a MES = 2 or an UCEIS = 5-6, while severe activity was defined by a MES = 3 or an UCEIS ≥ 7. IUS was performed within 4 weeks of endoscopy. The IBUS-SAS, the Milan Ultrasound Criteria (MUC)2, the UC-IUS score3, the US Score from Parente et al.4, and the Hata index5 were included in the analysis. Applicability of the Civitelli index6, an IUS score developed for pediatric patients, was also evaluated. The Spearman’s rank coefficient [rho = ρ] was used to perform correlations, while receiver operating characteristic (ROC) curves were compared with the Hanley & McNeil method.

Results

Collectively, 104 patients were included in the study. The majority of patients (61.5%) had extensive colitis (Montreal E3), with half of them having an active disease at endoscopy (54.8% using MES and 48.1% using UCEIS). IUS examination was performed at a median time of 8 days (IQR 2-15) after endoscopy. All the investigated scores were significantly able to distinguish between the 3 grades of severity of colonic inflammation, using both MES and UCEIS as a reference, with the exception of the Parente’s US Score for the severe endoscopic activity assessed with UCEIS [0 (IQR 0-1) for UCEIS < 7 vs 1 (IQR 0-1) for UCEIS ≥ 7, p=0.09]. The IBUS-SAS showed a strong correlation with endoscopic activity, both with MES (ρ = 0.71, p < 0.01) and UCEIS (ρ = 0.73, p < 0.01) assessments. The Area Under the Curve (AUC) of IBUS-SAS to detect an endoscopic activity of at least moderate severity (MES ≥ 2 and UCEIS ≥ 5) was 0.85 and 0.90, respectively. The optimal cutoff to detect a MES ≥ 2 and UCEIS ≥ 5 was > 11 (sensitivity 75% and specificity 82%) and > 22 (sensitivity 92% and specificity 80%), respectively. Both cut-offs showed progressive increase from mild to severe activity, with IBUS-SAS maintaining a consistently high AUC at different thresholds. Consistent with IBUS-SAS results, all the investigated UC-developed IUS scores correlated with both the MES and the UCEIS (p < 0.01). AUC values and relative comparisons between the AUC are detailed in Table 1.

Table 1. Relative comparisons between the AUC of each score to detect a MES ≥ 2 (A, top-right) and an UCEIS ≥ 5 (B, bottom-left) are reported.
Grey rows and columns: AUC values (with 95%CI).
White cells: p-values obtained via the Hanley and McNeil method (significant p-values are shown in bold).

A) AUC for MES ≥ 2
IBUS-SAS
0.85 (0.77-0.91)
Civitelli index
0.85 (0.76-0.91)
Hata index
0.77 (0.67-0.84)
US Score
0.74 (0.64-0.82)
UC-IUS
0.86 (0.78-0.92)


MUC
0.85 (0.77-0.91)
0.990.920.03< 0.010.55

UC-IUS
0.86 (0.78-0.92)
0.450.550.02< 0.01
0.62
Civitelli index
0.92 (0.83-0.95)
US Score
0.74 (0.64-0.82)
0.020.010.48
0.180.48Hata index
0.87 (0.79-0.93)
Hata index
0.77 (0.67-0.84)
0.060.02
0.450.090.20US Score
0.83 (0.75-0.90)
Civitelli index
0.85 (0.76-0.91)
0.93
0.090.300.950.50UC-IUS
0.92 (0.85-0.96)


0.920.050.240.980.59MUC
0.92 (0.85-0.96)


UC-IUS
0.92 (0.85-0.96)
US Score
0.83 (0.75-0.90)
Hata index
0.87 (0.79-0.93)
Civitelli index
0.92 (0.83-0.95)
IBUS-SAS
0.90 (0.83-0.95)
B) AUC for UCEIS ≥ 5

Conclusion

In this study we provide a successful validation of 6 IUS scores for UC. The IBUS-SAS has an optimal performance in predicting endoscopic activity also in patients with UC, despite having been developed initially for CD.

References

1. Novak KL, Nylund K, Maaser C, et al. Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. J Crohns Colitis 2021;15:609-616
2. Allocca M, Fiorino G, Bonovas S, et al. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis 2018;12:1385-1391
3. Bots S, Nylund K, Löwenberg M, et al. Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. J Crohns Colitis 2021;15:1264-1271
4. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010;105:1150-7
5. Kinoshita K, Katsurada T, Nishida M, et al. Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study. J Gastroenterol 2019;54:521-529
6. Civitelli F, Di Nardo G, Oliva S, et al. Ultrasonography of the colon in pediatric ulcerative colitis: a prospective, blind, comparative study with colonoscopy. J Pediatr 2014;165:78-84.e2

Disclosure

GD reports speaker fees from Alfasigma, Johnson & Johnson, Novartis, Pfizer, Takeda, and has served in advisory board for Celltrion Healthcare and Pfizer. The other authors have no conflict of interests to declare.

APPLICABILITY OF THE INTERNATIONAL BOWEL ULTRASOUND SEGMENTAL ACTIVITY SCORE (IBUS-SAS) TO ULCERATIVE COLITIS: A PROSPECTIVE STUDY

Tommaso Innocenti 1, Carmen Rocco 1, Erica Nicola Lynch 2, Michele Gatti 1, Siro Bagnoli 3, Unknown Unknown 3, Francesca Rogai 3, Beatrice Orlandini 3, Andrea Giovanni Bonanomi 3, Monica Milla 3, Stefano Milani 2, Andrea Galli 2, Maria Rosa Biagini 2, Gabriele Dragoni 1

1 Careggi University Hospital, Florence, Italy|||University of Florence, Florence, Italy

2 University of Florence, Florence, Italy

3 Careggi University Hospital, Florence, Italy

Event

UEG Week Vienna 2024

Topics

IBD Mechanisms & Personalised Medicine Radiology & Imaging

Submission format

Abstract

Session

IBD: Diagnosis and monitoring

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.